Efficacy and safety of entecavir compared to lamivudine in nucleoside-naïve patients with chronic hepatitis B: a randomized double-blind trial in China

Erratum to: Hepatol Int DOI 10.1007/s12072-007-9009-2

In the online and print edition of this article, the following statement appears incorrectly in the discussion section:

In HBeAg-positive patients, entecavir showed superiority over lamivudine for HBV DNA <300 (90% vs. 72%) and ALT normalization (78% vs. 71%).

The correct statement is as follows:

In HBeAg-negative patients, entecavir showed superiority over lamivudine for HBV DNA <300 (90% vs. 72%) and ALT normalization (78% vs. 71%).